Clinical-stage biotechnology company Spyre Therapeutics Inc (NASDAQ: SYRE) announced on Monday that it has commenced dosing of healthy volunteers in Phase 1 clinical trials of two investigational half-life extended anti-TL1A monoclonal antibodies.
The double blind, placebo-controlled single-ascending dose studies are being conducted in healthy volunteers, with each trial expected to enrol approximately 56 healthy adults.
Safety is the study's primary endpoint, with a secondary endpoint of pharmacokinetics (PK). Interim safety, PK and pharmacodynamic (PD) data from these trials are expected to be released in the second quarter of 2025.
Pending data from the Phase 1 trials, the company anticipates progressing the SPY002 programme into Phase 2 development in 2025.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA